Safety and Efficacy of CD19 CAR T-Cells Manufactured Post First HSCT and Administered Following a Second HSCT from a Different 10/10 HLA Matched Unrelated Donor to a Child with Multiple Relapsed B-ALL.

Wafaa Ahmed AlJizani; Erilda Kapllani; Sarah Courtney; Edbert Khong; Muhammad Kashif Ali; Yogi Raj Chopra; Tal Schechter; Sarah W. Alexander; Joerg Krueger

doi:10.1016/j.jtct.2025.12.285

Safety and Efficacy of CD19 CAR T-Cells Manufactured Post First HSCT and Administered Following a Second HSCT from a Different 10/10 HLA Matched Unrelated Donor to a Child with Multiple Relapsed B-ALL.

Transplantation and Cellular Therapy 2026

View at publisher

Authors: Wafaa Ahmed AlJizani, Erilda Kapllani, Sarah Courtney, Edbert Khong, Muhammad Kashif Ali, Yogi Raj Chopra, Tal Schechter, Sarah W. Alexander, Joerg Krueger

DOI: 10.1016/j.jtct.2025.12.285

Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Acute Lymphoblastic Leukemia research Hematopoietic Stem Cell Transplantation

Publication details

Journal / source: Transplantation and Cellular Therapy
Volume: 32
Issue: 2
Pages: S206–S207
Publication date: 1 February 2026
Language: EN